This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Out of public health concerns and given the current travel restrictions and lab closures worldwide because of COVID-19, the 27th International Symposium on Hepatitis C Virus and Related Viruses (HCV2020), scheduled to take place July 6 – 9, 2020 in Montreal, Canada has been postponed to July 6 - 9, 2021 and will now be delivered Virtually.



Mel Krajden

Medical Director
BC Centre for Disease Control Public Health Laboratory

Mel Krajden MD, FRCPC is the Medical Director of the BC Centre for Disease Control Public Health Laboratory and the Medical Head of Hepatitis at the British Columbia Centre for Disease Control. He is also a Professor of Pathology and Laboratory Medicine at the University of British Columbia.

His laboratory research involves in the application of molecular techniques to diagnose viruses, assess correlates between infection and clinical disease, and track microbial infections for epidemiological purposes. His clinical research involves integration of hepatitis prevention and care services which involves the use of linked laboratory and administrative data to help understand how to measure population level health outcomes for policy making.

He spearheads the BC-Hepatitis C Tester’s Cohort (BC-HTC). The BC-HTC contains de-identified health information on ~3.5 million British Columbians tested for HCV, HIV, HBV & TB. It includes almost all: lab tests/results, medical visits, hospitalizations, prescriptions, cancer outcomes, and mortality outcomes. With ~30 years of longitudinal information, the BC-HTC is able to determine health outcomes by different groups while adjusting for confounders. The goal is to drive value-based practices from the bench to population level -- translating discovery into practice across a range of health related questions.

He has extensive clinical trials expertise and has received CIHR funding in the fields of human papillomavirus, HIV and hepatitis C virus. He is a Co-PI/Mentor for CIHR funded Canadian Hepatitis C Network (CanHepC) and has >280 publications.